Dupilumab Treatment Provides Sustained Improvements Over 2 Years in Symptoms and Quality of Life in Adults with Atopic Dermatitis

Gil Yosipovitch, Marjolein de Bruin-Weller, April Armstrong, Jashin J Wu, Pedro Herranz, Diamant Thaçi, Dimittri Delevry, Gaëlle Bégo-Le Bagousse, Raymond Zhang, Brad Shumel, Ana B Rossi, Jingdong Chao, Gil Yosipovitch, Marjolein de Bruin-Weller, April Armstrong, Jashin J Wu, Pedro Herranz, Diamant Thaçi, Dimittri Delevry, Gaëlle Bégo-Le Bagousse, Raymond Zhang, Brad Shumel, Ana B Rossi, Jingdong Chao

Abstract

Introduction: Atopic dermatitis (AD) can have a profound negative impact on the quality of life (QoL) of patients. We analyzed the long-term changes in AD symptoms, QoL, and patient assessment of treatment effect in adults with moderate-to-severe AD treated for 2 years with dupilumab.

Methods: LIBERTY AD OLE (NCT01949311) is a multicenter, open-label extension (OLE) study in adults with moderate-to-severe AD who previously participated in dupilumab clinical trials (parent studies). Patients received dupilumab 300 mg weekly. Patient-Oriented Eczema Measure (POEM), Dermatology Life Quality Index (DLQI), EQ-5D-3L, and the Patient Global Assessment of Treatment Effect (PGATE) were assessed at weeks 48 and 100.

Results: A total of 2677 patients were included in the OLE, and 1028 completed week 100. By weeks 48 and 100, 94.1% and 95.6% of patients achieved a ≥ 4-point change in POEM from the parent study baseline (PSBL), respectively, and 93.3% and 93.4% of patients had achieved a ≥ 4-point change in DLQI from PSBL, respectively. At week 100, 35.1% of patients had a POEM score ≤ 2 (AD clear/almost clear) compared with 0.1% at PSBL, and 49.9% had a DLQI score of 0 or 1 (no effect at all on patient's life) compared with 1.5% at PSBL. At week 100, 74.5-97.3% of patients reported no effect of AD on the individual EQ-5D-3L domains, and 93.8% rated the effect of dupilumab treatment as "excellent," "very good," or "good" according to PGATE.

Conclusion: In adults with moderate-to-severe AD, dupilumab treatment over 2 years resulted in sustained improvements in patient-reported symptoms and QoL and a favorable patient perception of treatment effect.

Trial registration: ClinicalTrials.gov Identifier: NCT01949311. Supplementary material 1 (MP4 552250 kb).

Keywords: Adult; Atopic dermatitis; Clinical trial; Dermatology Life Quality Index; Dupilumab; EQ-5D; Efficacy; Long term; Patient-oriented eczema measure; Patient-reported outcomes.

© 2021. The Author(s).

Figures

Fig. 1
Fig. 1
Distribution of patients in categorical severities for a POEM and b DLQI at parent and OLE study baselines and at week 100. Analyses include patients with parent study baseline, OLE study baseline, and week 100 assessments. DLQI Dermatology Life Quality Index, OLE open-label extension, POEM Patient-Oriented Eczema Measure
Fig. 2
Fig. 2
Proportion of patients reporting the individual PGATE responses at weeks 48 and 100. Week 48 and week 100 analyses include patients with assessments at week 48 and week 100, respectively. PGATE Patient Global Assessment of Treatment Effect

References

    1. Haeck IM, ten Berge O, van Velsen SG, de Bruin-Weller MS, Bruijnzeel-Koomen CA, Knol MJ. Moderate correlation between quality of life and disease activity in adult patients with atopic dermatitis. J Eur Acad Dermatol Venereol. 2012;26(2):236–241. doi: 10.1111/j.1468-3083.2011.04043.x.
    1. Kim DH, Li K, Seo SJ, et al. Quality of life and disease severity are correlated in patients with atopic dermatitis. J Korean Med Sci. 2012;27(11):1327–1332. doi: 10.3346/jkms.2012.27.11.1327.
    1. Weidinger S, Beck LA, Bieber T, Kabashima K, Irvine AD. Atopic dermatitis. Nat Rev Dis Primers. 2018;4(1):1. doi: 10.1038/s41572-018-0001-z.
    1. European Medicines Agency. DUPIXENT® (dupilumab). Summary of product characteristics. . Accessed June 2021.
    1. US Food and Drug Administration. DUPIXENT® (dupilumab). Highlights of prescribing information. . Accessed June 2021.
    1. Simpson EL, Bieber T, Guttman-Yassky E, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335–2348. doi: 10.1056/NEJMoa1610020.
    1. Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017;389(10086):2287–2303. doi: 10.1016/S0140-6736(17)31191-1.
    1. de Bruin-Weller M, Thaçi D, Smith CH, et al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ) Br J Dermatol. 2018;178(5):1083–1101. doi: 10.1111/bjd.16156.
    1. Simpson EL, Paller AS, Siegfried EC, et al. Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial. JAMA Dermatol. 2020;156(1):44–56. doi: 10.1001/jamadermatol.2019.3336.
    1. Paller AS, Siegfried EC, Thaçi D, et al. Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: a randomized, double-blinded, placebo-controlled phase 3 trial. J Am Acad Dermatol. 2020;83(5):1282–1293. doi: 10.1016/j.jaad.2020.06.054.
    1. Beck LA, Thaçi D, Deleuran M, et al. Dupilumab provides favorable safety and sustained efficacy for up to 3 years in an open-label study of adults with moderate-to-severe atopic dermatitis. Am J Clin Dermatol. 2020;21(4):567–577. doi: 10.1007/s40257-020-00527-x.
    1. Charman CR, Venn AJ, Ravenscroft JC, Williams HC. Translating Patient-Oriented Eczema Measure (POEM) scores into clinical practice by suggesting severity strata derived using anchor-based methods. Br J Dermatol. 2013;169(6):1326–1332. doi: 10.1111/bjd.12590.
    1. Schram ME, Spuls PI, Leeflang MM, Lindeboom R, Bos JD, Schmitt J. EASI, (objective) SCORAD and POEM for atopic eczema: responsiveness and minimal clinically important difference. Allergy. 2012;67(1):99–106. doi: 10.1111/j.1398-9995.2011.02719.x.
    1. Basra MK, Fenech R, Gatt RM, Salek MS, Finlay AY. The Dermatology Life Quality Index 1994–2007: a comprehensive review of validation data and clinical results. Br J Dermatol. 2008;159(5):997–1035.
    1. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)–a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210–216. doi: 10.1111/j.1365-2230.1994.tb01167.x.
    1. Basra MK, Salek MS, Camilleri L, Sturkey R, Finlay AY. Determining the minimal clinically important difference and responsiveness of the Dermatology Life Quality Index (DLQI): further data. Dermatology. 2015;230(1):27–33. doi: 10.1159/000365390.
    1. EuroQoL. EuroQoL instruments. 2018. . Accessed June 2021.
    1. Hongbo Y, Thomas CL, Harrison MA, Salek MS, Finlay AY. Translating the science of quality of life into practice: what do dermatology life quality index scores mean? J Invest Dermatol. 2005;125(4):659–664. doi: 10.1111/j.0022-202X.2005.23621.x.
    1. Simpson EL, Beck LA, Wu R, et al. Correlation between clinical and patient-reported outcomes in patients with moderate-to-severe atopic dermatitis in a phase 2 clinical trial of dupilumab. Poster presented at 23rd World Congress of Dermatology (WCD); Vancouver; 2015.
    1. Kimball AB, Yves P, Stephen T, et al. Interpretation of EASI-75 from a patient perspective—a post hoc analysis from a phase 2b trial of dupilumab in adults with moderate-to-severe atopic dermatitis. JAAD. 2017;76(6 Suppl 1):416.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj